ABSTRACT
This study has evaluated the anti-inflammatory and analgesic responses of etoricoxib, a selective COX-2 non-steroidal anti-inflammatory drug combined with misoprostol in pre-clinical assays. Groups of animals (mice and rats) were subjected to rat's paw edema induced by carrageenan, and writhing and formalin tests in mice. Treatment with etoricoxib, misoprostol, and etoricoxib combined with misoprostol inhibited the inflammation process by 35 %, 30 %, and 61 %, respectively in the rat paw edema induced by carrageenan with the greatest effects being obtained in the group treated with etoricoxib combined to misoprostol. In the writhing test, etoricoxib inhibited the number of writhes by 33 %, and by 27 % when combined with misoprostol. In the first phase of the formalin test (nociceptive), treatment with the combination of etoricoxib and misoprostol inhibited significantly this process by 45 %, while in the second phase (inflammatory), etoricoxib inhibited this by 97 %, the etoricoxib + misoprostol inhibited this by 78 %, respectively. The responses observed have demonstrated that the combination of etoricoxib and misoprostol increased the anti-inflammatory response, but it did not show effect in the peripheral analgesic response.
Subject(s)
Anti-Ulcer Agents/pharmacology , Cyclooxygenase 2 Inhibitors/pharmacology , Misoprostol/pharmacology , Pyridines/pharmacology , Sulfones/pharmacology , Analysis of Variance , Animals , Carrageenan , Cyclooxygenase 2 Inhibitors/adverse effects , Drug Evaluation, Preclinical , Drug Synergism , Drug Therapy, Combination , Edema/chemically induced , Edema/prevention & control , Etoricoxib , Male , Mice , Pain/chemically induced , Pain/prevention & control , Pain Measurement , Pyridines/adverse effects , Rats , Rats, Wistar , Sulfones/adverse effectsABSTRACT
The anti-inflammatory effect of Causticum was evaluated using acute and chronic inflammatory models in vivo. The administration of concentrated Causticum solution into the hind paw of rats produced an inflammatory reaction with oedema formation within the first hour, showing that Causticum acts as an oedematogenic agent. Carrageenin induced rat paw oedema was significantly inhibited (P<0.05) in the group treated with Causticum 30cH solution compared to control. Groups treated with potentized Causticum (6cH, 12cH, 30cH and 200cH), showed significant inhibition (P<0.05) of the inflammation pre-induced by carrageenin. However pre-treatment with Causticum 30cH for 6 days (0.5 ml, daily) did not significantly inhibit granulation using an implantation method.
Subject(s)
Anti-Inflammatory Agents/administration & dosage , Calcium Hydroxide/pharmacology , Edema/drug therapy , Foot Diseases/chemically induced , Inflammation/drug therapy , Phytotherapy , Plant Extracts/administration & dosage , Potassium Compounds/pharmacology , Animals , Calcium Hydroxide/administration & dosage , Carrageenan , Disease Models, Animal , Dose-Response Relationship, Drug , Edema/chemically induced , Granulation Tissue/drug effects , Inflammation/chemically induced , Male , Potassium Compounds/administration & dosage , Random Allocation , Rats , Rats, Wistar , Time FactorsABSTRACT
The anti-inflammatory effect of Causticum was evaluated using acute and chronic inflammatory models in vivo. The administration of concentrated Causticum solution into the hind paw of rats produced an inflammatory reaction with oedema formation within the first hour, showing..(AU)
